Increase in shares and capital through the exercise of stock acquisition rights
First written in FY2020-Q1. 12 of 14 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2025.
102 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「1 August 2024 to 31 July 2025 3,500 1,524,700 3,003 570,405 3,003 486,905 (Note 1) Increase through the exercise of stock acquisition rights.」
During the consolidated fiscal year, the number of shares increased by 3,500 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥3.003 million. - FY2025-H1AdvancedAnnual report
「1 August 2024–31 January 2025 500 1,521,700 432 567,835 432 484,335 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the interim consolidated accounting period, the number of shares increased by 500 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥432,000. - FY2024AdvancedAnnual report
「1 August 2023 to 31 July 2024 113,640 1,521,200 92,448 567,402 92,448 483,902 (Note) Increase through the exercise of stock acquisition rights.」
During the consolidated fiscal year, the number of shares increased by 113,640 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥92.448 million. - FY2024-Q3AdvancedAnnual report
「The number of shares issued through the exercise of stock acquisition rights from 1 June 2024 through the filing date of this quarterly report is not included in the “Number of shares issued as of the filing date” field.」
Against 1,469,360 issued shares at the end of the third quarter, the number issued as of the filing date was 1,508,860, indicating that shares continued to be issued through the exercise of stock acquisition rights after period-end. - FY2024-Q2AdvancedAnnual report
「Proceeds from the issuance of shares through the exercise of stock acquisition rights increased stated capital and capital surplus by ¥53.074 million each, while」
Through the exercise of stock acquisition rights, stated capital and capital surplus each increased by ¥53.074 million. Proceeds from the issuance of shares under financing activities totaled ¥105.446 million. - FY2024-Q1AdvancedAnnual report
「1 August 2023–31 October 2023 61,600 1,469,160 52,901 527,854 52,901 444,354 (Note) Increase resulting from the exercise of stock acquisition rights.」
From August to October 2023, the number of shares increased by 61,600 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥52.901 million. - FY2023-Q3AdvancedAnnual report
「In addition, the number of shares increased by 9,600 through the exercise of stock options from 1 May 2023 onward.」
The company stated that the number of issued shares as of the filing date had increased by 9,600 through the exercise of stock options from 1 May 2023 onward. - FY2022AdvancedAnnual report
「Number of bonds with stock acquisition rights, etc., with an exercise price adjustment clause exercised during the period 816」
During the fiscal year, 816 rights representing 81,600 shares under the third series of stock acquisition rights were exercised, raising ¥186.076 million. The annual increase in issued shares through the exercise of stock acquisition rights was 82,800, while stated capital and capital surplus each increased by ¥94.029 million. - FY2022-Q3AdvancedAnnual report
「1 February 2022–30 April 2022 600 1,345,560 303 396,241 303 312,741 (Note) Increase resulting from the exercise of stock acquisition rights.」
From 1 February to 30 April 2022, the number of shares increased by 600 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥303,000. - FY2022-Q1AdvancedAnnual report
「Net assets at the end of the first quarter consolidated accounting period increased by ¥138.943 million from the end of the previous consolidated fiscal year to ¥700.470 million. This was mainly due to increases of ¥93.422 million each in stated capital and capital surplus through the exercise of stock acquisition rights.」
Through the exercise of stock acquisition rights, stated capital and capital surplus each increased by ¥93.422 million, and the total number of issued shares was 1,344,960 as of 31 October 2021. - FY2021AchievedAnnual report
「After the end of the consolidated fiscal year and by 11 October 2021, the third series of stock acquisition rights issued through a third-party allotment, with a provision for adjustment of the exercise price, had been exercised. The details are as follows. The third series of stock acquisition rights with an exercise-price adjustment provision, issued by the company on 5 July 2021, had been fully exercised as of 11 October 2021.」
Regarding the third series of stock acquisition rights, 816 rights representing 81,600 shares had been exercised by 11 October 2021, completing the exercise of all rights. - FY2020AdvancedAnnual report
「Proceeds from the issuance of shares through the exercise of stock acquisition rights ¥11.293 million」
During the consolidated fiscal year, the number of shares increased by 11,160 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥5.646 million. - FY2020-Q2AdvancedAnnual report
「1 November 2019 to 31 January 2020」
During the second quarter accounting period, the number of shares increased by 1,200 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥607,000. The total number of issued shares was 1,254,960. - FY2020-Q1First statedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
From 1 August to 31 October 2019, the number of shares increased by 9,960 through the exercise of stock acquisition rights, while stated capital and capital surplus each increased by ¥5.039 million.